Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report

Mov Disord. 2004 Oct;19(10):1243-4. doi: 10.1002/mds.20164.

Abstract

We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / drug therapy*
  • Botulinum Toxins, Type A / therapeutic use
  • Cholinesterase Inhibitors / adverse effects*
  • Cholinesterase Inhibitors / therapeutic use
  • Cognition Disorders / diagnosis
  • Cognition Disorders / drug therapy
  • Dystonia / chemically induced*
  • Dystonia / drug therapy
  • Dystonia / physiopathology
  • Female
  • Galantamine / adverse effects*
  • Galantamine / therapeutic use
  • Humans
  • Neuromuscular Agents / therapeutic use
  • Neuropsychological Tests
  • Severity of Illness Index
  • Syndrome

Substances

  • Cholinesterase Inhibitors
  • Neuromuscular Agents
  • Galantamine
  • Botulinum Toxins, Type A